May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc.

Catalyst pharmaceuticals competitors

As of June 30, 2020, the last business day of the Registrant's most recently completed second quarter, the aggregate market value of all voting, and non-voting common equity held by non-affiliates was $444,887,344. short beautiful words for mom

82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. Shares of Catalyst Pharmaceuticals Inc. . 55% to $162. . . 44% to $17. .

.

(CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth.

Catalyst Pharmaceuticals Inc.

.

.

.

09 below its 52-week high ($22.

. Now, Catalyst is suing the agency over last month’s approval of Jacobus’ drug. 11), which the company achieved on January 13th.

.

Shares of Catalyst Pharmaceuticals Inc.

.

11), which the company achieved on January 13th.

25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings.

. CPRX, +2.

staar score conversion chart

A number of factors, including (i) the scope of protection from competition provided by the patent, and (ii) those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2019.

36% higher to $16.

.

02% rallied 1.

36% higher to $16. . As you might. , March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.

Salaries vary by department as.

Reuters Graphics

Catalyst Pharmaceuticals Inc. 55% to $162. Competitor Summary. 09 below its 52-week high ($22. . CPRX advanced 1. Oct 10, 2022 · Catalyst Pharmaceuticals CPRX stock has skyrocketed 80. (CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth. 02% to $12. . 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. Shares of Catalyst Pharmaceuticals Inc. .

30% to $12. . . .

.

.

.

.

.

.

. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company. 1 day ago · For Immediate ReleaseChicago, IL – May 24, 2023 – Today, Zacks Equity Research discusses Amphastar Pharmaceuticals AMPH, Dr. CPRX shed 1. For the Biotechnology subindustry, Catalyst Pharmaceuticals's WACC %, along with its competitors' market caps and WACC % data, can be viewed below: * Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the. Reddy’s Laboratories RDY and Teva Pharmaceutical TEVA.

.

. Catalyst Pharmaceuticals top competitors are SMP Pharmacy Solutions, BRCR Global and Biotest Pharmaceuticals Corporation and they have annual revenue of $17. May 23, 2023 · The main competitors of Catalyst Pharmaceuticals include Ligand Pharmaceuticals (LGND), Pliant Therapeutics (PLRX), Arcus Biosciences (RCUS), 89bio (ETNB), Keros Therapeutics (KROS), OPKO Health (OPK), Arvinas (ARVN), Agios Pharmaceuticals (AGIO), MoonLake Immunotherapeutics (MLTX), and Travere Therapeutics (TVTX).